Evaluating the Role and Efficacy of Cobenfy (Xanomeline and Trospium Chloride) in Schizophrenia Treatment - review
Schizophrenia is a complex psychiatric disorder often resistant to dopamine-targeting antipsychotics. Cobenfy, a combination of xanomeline and trospium chloride, offers a novel approach by modulating muscarinic receptors while minimizing side effects. This review evaluates its efficacy and safety,...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nicolaus Copernicus University in Toruń
2025-04-01
|
| Series: | Quality in Sport |
| Subjects: | |
| Online Access: | https://apcz.umk.pl/QS/article/view/59815 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849709981130031104 |
|---|---|
| author | Michał Mazur Katarzyna Żak Katarzyna Michalak Krystian Zukierski Weronika Jarych Aleksandra Pliszka Hubert Jucha Katarzyna Madyniak Agnieszka Kluz |
| author_facet | Michał Mazur Katarzyna Żak Katarzyna Michalak Krystian Zukierski Weronika Jarych Aleksandra Pliszka Hubert Jucha Katarzyna Madyniak Agnieszka Kluz |
| author_sort | Michał Mazur |
| collection | DOAJ |
| description |
Schizophrenia is a complex psychiatric disorder often resistant to dopamine-targeting antipsychotics. Cobenfy, a combination of xanomeline and trospium chloride, offers a novel approach by modulating muscarinic receptors while minimizing side effects. This review evaluates its efficacy and safety, particularly in treatment-resistant cases. Clinical trials show significant reductions in both positive and negative symptoms, positioning Cobenfy as a promising alternative.
|
| format | Article |
| id | doaj-art-b6be33672a564ff7b1228d219f469bc6 |
| institution | DOAJ |
| issn | 2450-3118 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Nicolaus Copernicus University in Toruń |
| record_format | Article |
| series | Quality in Sport |
| spelling | doaj-art-b6be33672a564ff7b1228d219f469bc62025-08-20T03:15:04ZengNicolaus Copernicus University in ToruńQuality in Sport2450-31182025-04-014010.12775/QS.2025.40.59815Evaluating the Role and Efficacy of Cobenfy (Xanomeline and Trospium Chloride) in Schizophrenia Treatment - reviewMichał Mazur0https://orcid.org/0009-0007-8157-5293Katarzyna Żak 1https://orcid.org/0009-0006-4036-090XKatarzyna Michalak 2https://orcid.org/0009-0005-0856-1536Krystian Zukierski 3https://orcid.org/0009-0008-1428-5744Weronika Jarych4https://orcid.org/0009-0009-1335-8072Aleksandra Pliszka 5https://orcid.org/0009-0003-5938-5929Hubert Jucha 6https://orcid.org/0009-0002-0182-627XKatarzyna Madyniak 7https://orcid.org/0009-0003-6927-3832Agnieszka Kluz 8https://orcid.org/0009-0006-7427-5818Saint Adalbert Hospital in Gdańsk, aleja Jana Pawła II 50, 80-462 Gdańsk, PolandSaint Adalbert Hospital in Gdańsk, aleja Jana Pawła II 50, 80-462 Gdańsk, PolandSzpital Morski im. PCK in Gdynia, Powstania Styczniowego 1, 81-519 Gdynia, PolandSzpital Morski im. PCK in Gdynia, Powstania Styczniowego 1, 81-519 Gdynia, PolandSzpital Morski im. PCK in Gdynia, Powstania Styczniowego 1, 81-519 Gdynia, PolandSaint Adalbert Hospital in Gdańsk, aleja Jana Pawła II 50, 80-462 Gdańsk, PolandFundacja Zdrowie, Wilhelma Konrada Roentgena 23, 02-781 Warszawa, PolandMedical University of Warsaw, Żwirki I Wigury 61, 02-091 Warszawa, PolandWolski Hospital, Kasprzaka 17, 01-211 Warszawa, Poland Schizophrenia is a complex psychiatric disorder often resistant to dopamine-targeting antipsychotics. Cobenfy, a combination of xanomeline and trospium chloride, offers a novel approach by modulating muscarinic receptors while minimizing side effects. This review evaluates its efficacy and safety, particularly in treatment-resistant cases. Clinical trials show significant reductions in both positive and negative symptoms, positioning Cobenfy as a promising alternative. https://apcz.umk.pl/QS/article/view/59815Cobenfyxanomeline-trospiummuscarinic receptor modulationschizophrenia treatmentnon-dopaminergic antipsychoticsEMERGENT trials |
| spellingShingle | Michał Mazur Katarzyna Żak Katarzyna Michalak Krystian Zukierski Weronika Jarych Aleksandra Pliszka Hubert Jucha Katarzyna Madyniak Agnieszka Kluz Evaluating the Role and Efficacy of Cobenfy (Xanomeline and Trospium Chloride) in Schizophrenia Treatment - review Quality in Sport Cobenfy xanomeline-trospium muscarinic receptor modulation schizophrenia treatment non-dopaminergic antipsychotics EMERGENT trials |
| title | Evaluating the Role and Efficacy of Cobenfy (Xanomeline and Trospium Chloride) in Schizophrenia Treatment - review |
| title_full | Evaluating the Role and Efficacy of Cobenfy (Xanomeline and Trospium Chloride) in Schizophrenia Treatment - review |
| title_fullStr | Evaluating the Role and Efficacy of Cobenfy (Xanomeline and Trospium Chloride) in Schizophrenia Treatment - review |
| title_full_unstemmed | Evaluating the Role and Efficacy of Cobenfy (Xanomeline and Trospium Chloride) in Schizophrenia Treatment - review |
| title_short | Evaluating the Role and Efficacy of Cobenfy (Xanomeline and Trospium Chloride) in Schizophrenia Treatment - review |
| title_sort | evaluating the role and efficacy of cobenfy xanomeline and trospium chloride in schizophrenia treatment review |
| topic | Cobenfy xanomeline-trospium muscarinic receptor modulation schizophrenia treatment non-dopaminergic antipsychotics EMERGENT trials |
| url | https://apcz.umk.pl/QS/article/view/59815 |
| work_keys_str_mv | AT michałmazur evaluatingtheroleandefficacyofcobenfyxanomelineandtrospiumchlorideinschizophreniatreatmentreview AT katarzynazak evaluatingtheroleandefficacyofcobenfyxanomelineandtrospiumchlorideinschizophreniatreatmentreview AT katarzynamichalak evaluatingtheroleandefficacyofcobenfyxanomelineandtrospiumchlorideinschizophreniatreatmentreview AT krystianzukierski evaluatingtheroleandefficacyofcobenfyxanomelineandtrospiumchlorideinschizophreniatreatmentreview AT weronikajarych evaluatingtheroleandefficacyofcobenfyxanomelineandtrospiumchlorideinschizophreniatreatmentreview AT aleksandrapliszka evaluatingtheroleandefficacyofcobenfyxanomelineandtrospiumchlorideinschizophreniatreatmentreview AT hubertjucha evaluatingtheroleandefficacyofcobenfyxanomelineandtrospiumchlorideinschizophreniatreatmentreview AT katarzynamadyniak evaluatingtheroleandefficacyofcobenfyxanomelineandtrospiumchlorideinschizophreniatreatmentreview AT agnieszkakluz evaluatingtheroleandefficacyofcobenfyxanomelineandtrospiumchlorideinschizophreniatreatmentreview |